Polyclonal Antibody Market, by Type (Primary Antibody and Secondary Antibody), by Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Oppor

Polyclonal Antibody Market, by Type (Primary Antibody and Secondary Antibody), by Application (Academic Research and Commercial), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Antibodies are the type of globular proteins produced by the plasma cells. Polyclonal antibodies are produced by different types of plasma B cells and bind to different epitopes in the same antigen. Polyclonal antibodies are heterogeneous mixture of antibodies and are inexpensive to produce. Polyclonal antibodies are used in therapeutics as well as in research applications.
Market Dynamics
Rising incidence of cancer is expected to drive the global polyclonal antibody market growth. For instance, according to an article published by the Cancer Research UK, 367,167 new cases of cancer were reported between 2015 and 2017 in the U.K.
Moreover, ongoing development of polyclonal antibodies is expected to drive the market growth. For instance, in March 2020, GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced that the company is developing a recombinant polyclonal antibody therapy for the treatment of COVID-19. The recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG) is in development to treat high-risk and severely ill individuals infected with COVID-19.
Key features of the study:
This report provides in-depth analysis of the global polyclonal antibody market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global polyclonal antibody market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB. and GeneTex, Inc. among others.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global polyclonal antibody market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polyclonal antibody market.
Detailed Segmentation:
Global Polyclonal Antibody Market, By Type:
Primary Antibody
Secondary Antibody
Global Polyclonal Antibody Market, By Application:
Academic Research
Commercial
Global Polyclonal Antibody Market, By Region:
North America
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country:
U.S.
Canada
Latin America
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type:
Primary Antibody
Secondary Antibody
By Application:
Academic Research
Commercial
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abcam plc*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
GenScript
Merck KGaA.
IgY Immune Technologies & Life Sciences Inc.
Thermo Fisher Scientific Inc.
Takara Bio Inc.
Genway Biotech, Inc.
Geno Technology Inc.
DC Biosciences Ltd.
Good Biotech Corp
Rockland Immunochemicals, Inc.
EpiGentek Group Inc.
Innovagen AB
GeneTex, Inc.
“*” marked represents similar segmentation in other categories in the respective section.